





















RCOXIA (etoricoxib, MSD)

THE POWER TO MOVE YOU

לפני מתן מרשם יש לעיין בעלון לרופא כפי שאושר ע"י משרד הבריאות *למצבים המופיעים בהתוויה

Therapeutic Indications1:

For the symptomatic relief of osteoarthritis (OA) (30 mg and 60 mg), rheumatoid arthritis (RA) (90 mg), ankylosing spondylitis (90 mg), and the pain and signs of inflammation associated with acute gouty arthritis (120 mg). For the short-term treatment of moderate pain associated with dental surgery (90 mg). Contraindications: • Hypersensitivity to the active substance or to any of the excipients. • Active peptic ulceration or active gastro-intestinal (GI) bleeding. • Patients who have experienced bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria, or allergic-type reactions after taking acetylsalicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors. • Pregnancy and lactation. • Severe hepatic dysfunction (serum albumin <25 g/I or Child-Pugh score ≥10) • Estimated renal creatinine clearance <30 ml/min. • Children and adolescents under 16 years of age. • Inflammatory bowel disease. • Congestive heart failure (NYHA II-IV) • Patients with hypertension whose blood pressure is persistently elevated above 140/90mmHg and has not been adequately controlled. • Established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease.

For special warnings, precautions for use and common/clinically significant adverse events, please refer to the Physicians information leaflet

עלון לרופא כפי שאושר ע"י משרד הבריאות בישראל .1

2. Matsumoto AK, Melian A, Mandel DR, et al; for Etoricoxib Rheumatoid Arthritis Study Group. A randomized, controlled, linical trial of Etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol. 2002;29(8): 1623-1630.



Copyright © Merck Sharp & Dohme (Israel-1996) Company Ltd., 2013. All rights reserved, MUSC-1093234-0000

יעילות: זמן ממוצע לרה-מדיקציה





